Drug Landscape ›
PHENAZOPYRIDINE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 2,370
Most-reported reactions
Chronic Kidney Disease — 331 reports (13.97%) Pain — 294 reports (12.41%) Nausea — 276 reports (11.65%) Urinary Tract Infection — 253 reports (10.68%) Fatigue — 230 reports (9.7%) Diarrhoea — 215 reports (9.07%) Acute Kidney Injury — 212 reports (8.95%) Renal Failure — 206 reports (8.69%) Anxiety — 182 reports (7.68%) Vomiting — 171 reports (7.22%)
Source database →
PHENAZOPYRIDINE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is PHENAZOPYRIDINE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for PHENAZOPYRIDINE in United States?
Marketing authorisation holder not available in our data.